Phase 1b Study of CX11 Tablets for Obesity by Corxel Pharmaceuticals
Corxel Pharmaceuticals is conducting Phase 1b study to evaluate the safety and tolerability of CX11 tablets in participants with obesity or overweight.
Company
Pharmaceutical intelligence for Corxel Pharmaceuticals with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.